Gastric cancer (GC) occupies the first few places in the world among tumors in terms of incidence and mortality, causing serious harm to human health, and at the same time, its treatment greatly consumes the health care resources of all countries in the world. The diagnosis of GC is usually based on histopathologic examination, and it is very important to be able to detect and identify cancerous lesions at an early stage, but some endoscopists' lack of diagnostic experience and fatigue at work lead to a certain rate of under diagnosis. The rapid and striking development of Artificial intelligence (AI) has helped to enhance the ability to extract abnormal information from endoscopic images to some extent, and more and more researchers are applying AI technology to the diagnosis of GC. This initiative has not only improved the detection rate of early gastric cancer (EGC), but also significantly improved the survival rate of patients after treatment. This article reviews the results of various AI-assisted diagnoses of EGC in recent years, including the identification of EGC, the determination of differentiation type and invasion depth, and the identification of borders. Although AI has a better application prospect in the early diagnosis of ECG, there are still major challenges, and the prospects and limitations of AI application need to be further discussed.

With the rapid advancement of artificial intelligence (AI) technologies, including deep learning, large language models, and neural networks, these methodologies are increasingly being developed and integrated into cancer research. Gastrointestinal tumors are characterized by complexity and heterogeneity, posing significant challenges for early detection, diagnostic accuracy, and the development of personalized treatment strategies. The application of AI in digestive oncology has demonstrated its transformative potential. AI not only alleviates the diagnostic burden on clinicians, but it improves tumor screening sensitivity, specificity, and accuracy. Additionally, AI aids the detection of biomarkers such as microsatellite instability and mismatch repair, supports intraoperative assessments of tumor invasion depth, predicts treatment responses, and facilitates the design of personalized treatment plans to potentially significantly enhance patient outcomes. Moreover, the integration of AI with multiomics analyses and imaging technologies has led to substantial advancements in foundational research on the tumor microenvironment. This review highlights the progress of AI in gastrointestinal oncology over the past 5 years with focus on early tumor screening, diagnosis, molecular marker identification, treatment planning, and prognosis predictions. We also explored the potential of AI to enhance medical imaging analyses to aid tumor detection and characterization as well as its role in automating and refining histopathological assessments.

The advent of artificial intelligence (AI) and deep learning algorithms, particularly convolutional neural networks, promises to address pitfalls, bridging the care for patients at high risk with improved detection (computer-aided detection [CADe]) and characterization (computer-aided diagnosis [CADx]) of lesions. This review describes the available artificial intelligence (AI) technology and the current data on AI tools for screening esophageal squamous cell cancer, Barret's esophagus-related neoplasia, and gastric cancer. These tools outperformed endoscopists in many situations. Recent randomized controlled trials have demonstrated the successful application of AI tools in clinical practice with improved outcomes.

At a population level, the European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter and Microbiota Study Group (EHMSG), and the European Society of Pathology (ESP) suggest endoscopic screening for gastric cancer (and precancerous conditions) in high-risk regions (age-standardized rate [ASR] > 20 per 100 000 person-years) every 2 to 3 years or, if cost-effectiveness has been proven, in intermediate risk regions (ASR 10-20 per 100 000 person-years) every 5 years, but not in low-risk regions (ASR < 10).ESGE/EHMSG/ESP recommend that irrespective of country of origin, individual gastric risk assessment and stratification of precancerous conditions is recommended for first-time gastroscopy. ESGE/EHMSG/ESP suggest that gastric cancer screening or surveillance in asymptomatic individuals over 80 should be discontinued or not started, and that patients' comorbidities should be considered when treatment of superficial lesions is planned.ESGE/EHMSG/ESP recommend that a high quality endoscopy including the use of virtual chromoendoscopy (VCE), after proper training, is performed for screening, diagnosis, and staging of precancerous conditions (atrophy and intestinal metaplasia) and lesions (dysplasia or cancer), as well as after endoscopic therapy. VCE should be used to guide the sampling site for biopsies in the case of suspected neoplastic lesions as well as to guide biopsies for diagnosis and staging of gastric precancerous conditions, with random biopsies to be taken in the absence of endoscopically suspected changes. When there is a suspected early gastric neoplastic lesion, it should be properly described (location, size, Paris classification, vascular and mucosal pattern), photodocumented, and two targeted biopsies taken.ESGE/EHMSG/ESP do not recommend routine performance of endoscopic ultrasonography (EUS), computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT prior to endoscopic resection unless there are signs of deep submucosal invasion or if the lesion is not considered suitable for endoscopic resection.ESGE/EHMSG/ESP recommend endoscopic submucosal dissection (ESD) for differentiated gastric lesions clinically staged as dysplastic (low grade and high grade) or as intramucosal carcinoma (of any size if not ulcerated or ≤ 30 mm if ulcerated), with EMR being an alternative for Paris 0-IIa lesions of size ≤ 10 mm with low likelihood of malignancy.ESGE/EHMSG/ESP suggest that a decision about ESD can be considered for malignant lesions clinically staged as having minimal submucosal invasion if differentiated and ≤ 30 mm; or for malignant lesions clinically staged as intramucosal, undifferentiated and ≤ 20 mm; and in both cases with no ulcerative findings.ESGE/EHMSG/ESP recommends patient management based on the following histological risk after endoscopic resection: Curative/very low-risk resection (lymph node metastasis [LNM] risk < 0.5 %-1 %): en bloc R0 resection; dysplastic/pT1a, differentiated lesion, no lymphovascular invasion, independent of size if no ulceration and ≤ 30 mm if ulcerated. No further staging procedure or treatment is recommended.Curative/low-risk resection (LNM risk < 3 %): en bloc R0 resection; lesion with no lymphovascular invasion and: a) pT1b, invasion ≤ 500 µm, differentiated, size ≤ 30 mm; or b) pT1a, undifferentiated, size ≤ 20 mm and no ulceration. Staging should be completed, and further treatment is generally not necessary, but a multidisciplinary discussion is required. Local-risk resection (very low risk of LNM but increased risk of local persistence/recurrence): Piecemeal resection or tumor-positive horizontal margin of a lesion otherwise meeting curative/very low-risk criteria (or meeting low-risk criteria provided that there is no submucosal invasive tumor at the resection margin in the case of piecemeal resection or tumor-positive horizontal margin for pT1b lesions [invasion ≤ 500 µm; well-differentiated; size ≤ 30 mm, and VM0]). Endoscopic surveillance/re-treatment is recommended rather than other additional treatment. High-risk resection (noncurative): Any lesion with any of the following: (a) a positive vertical margin (if carcinoma) or lymphovascular invasion or deep submucosal invasion (> 500 µm from the muscularis mucosae); (b) poorly differentiated lesions if ulceration or size > 20 mm; (c) pT1b differentiated lesions with submucosal invasion ≤ 500 µm with size > 30 mm; or (d) intramucosal ulcerative lesion with size > 30 mm. Complete staging and strong consideration for additional treatments (surgery) in multidisciplinary discussion.ESGE/EHMSG/ESP suggest the use of validated endoscopic classifications of atrophy (e. g. Kimura-Takemoto) or intestinal metaplasia (e. g. endoscopic grading of gastric intestinal metaplasia [EGGIM]) to endoscopically stage precancerous conditions and stratify the risk for gastric cancer.ESGE/EHMSG/ESP recommend that biopsies should be taken from at least two topographic sites (2 biopsies from the antrum/incisura and 2 from the corpus, guided by VCE) in two separate, clearly labeled vials. Additional biopsy from the incisura is optional.ESGE/EHMSG/ESP recommend that patients with extensive endoscopic changes (Kimura C3 + or EGGIM 5 +) or advanced histological stages of atrophic gastritis (severe atrophic changes or intestinal metaplasia, or changes in both antrum and corpus, operative link on gastritis assessment/operative link on gastric intestinal metaplasia [OLGA/OLGIM] III/IV) should be followed up with high quality endoscopy every 3 years, irrespective of the individual's country of origin.ESGE/EHMSG/ESP recommend that no surveillance is proposed for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history, incomplete intestinal metaplasia, persistent H. pylori infection). This group constitutes most individuals found in clinical practice.ESGE/EHMSG/ESP recommend H. pylori eradication for patients with precancerous conditions and after endoscopic or surgical therapy.ESGE/EHMSG/ESP recommend that patients should be advised to stop smoking and low-dose daily aspirin use may be considered for the prevention of gastric cancer in selected individuals with high risk for cardiovascular events.

Accurate detection and segmentation of esophageal lesions are crucial for diagnosing and treating gastrointestinal diseases. However, early detection of esophageal cancer remains challenging, contributing to a reduced five-year survival rate among patients. This paper introduces a novel multitask deep learning model for automatic diagnosis that integrates classification and segmentation tasks to assist endoscopists effectively. Our approach leverages the MobileNetV2 deep learning architecture enhanced with a mutual attention module, significantly improving the model's performance in determining the locations of esophageal lesions. Unlike traditional models, the proposed model is designed not to replace endoscopists but to empower them to correct false predictions when provided with additional Supporting Information. We evaluated the proposed model on three well-known data sets: Early Esophageal Cancer (EEC), CVC-ClinicDB, and KVASIR. The experimental results demonstrate promising performance, achieving high classification accuracies of 98.72% (F1-score: 98.08%) on CVC-ClinicDB, 98.95% (F1-score: 98.32%) on KVASIR, and 99.12% (F1-score: 99.00%) on our generated EEC data set. Compared to state-of-the-art models, our classification results show significant improvement. For the segmentation task, the model attained a Dice coefficient of 92.73% and an Intersection over Union (IoU) of 91.54%. These findings suggest that the proposed multitask deep learning model can effectively assist endoscopists in evaluating esophageal lesions, thereby alleviating their workload and enhancing diagnostic precision.

Artificial intelligence (AI) has shown immense potential in the field of medicine, but its actual effectiveness and safety still need to be validated through clinical trials. Currently, the research themes, methodologies, and development trends of AI-related clinical trials remain unclear, and further exploration of these studies will be crucial for uncovering AI's practical application potential and promoting its broader adoption in clinical settings.

To analyze the current status, hotspots, and trends of published clinical research on AI applications.

Publications related to AI clinical applications were retrieved from the Web of Science database. Relevant data were extracted using VOSviewer 1.6.17 to generate visual cooperation network maps for countries, organizations, authors, and keywords. Burst citation detection for keywords and citations was performed using CiteSpace 5.8.R3 to identify sudden surges in citation frequency within a short period, and the theme evolution was analyzed using SciMAT to track the development and trends of research topics over time.

A total of 22,583 articles were obtained from the Web of Science database. Seven-hundred and thirty-five AI clinical application research were published by 1764 institutions from 53 countries. The majority of publications were contributed by the United States, China, and the UK. Active collaborations were noted among leading authors, particularly those from developed countries. The publications mainly focused on evaluating the application value of AI technology in the fields of disease diagnosis and classification, disease risk prediction and management, assisted surgery, and rehabilitation. Deep learning and chatbot technologies were identified as emerging research hotspots in recent studies on AI applications.

A total of 735 articles on AI in clinical research were analyzed, with publication volume and citation counts steadily increasing each year. Institutions and researchers from the United States contributed the most to the research output in this field. Key areas of focus included AI applications in surgery, rehabilitation, disease diagnosis, risk prediction, and health management, with emerging trends in deep learning and chatbots. This study also provides detailed and intuitive information about important articles, journals, core authors, institutions, and topics in the field through visualization maps, which will help researchers quickly understand the current status, hotspots, and trends of artificial intelligence clinical application research. Future clinical trials of artificial intelligence should strengthen scientific design, ethical compliance, and interdisciplinary and international cooperation and pay more attention to its practical clinical value and reliable application in diverse scenarios.

This article discusses the manuscript recently published in the World Journal of Gastroenterology, which explores the application of deep learning models in decision-making processes via wireless capsule endoscopy. Integrating artificial intelligence (AI) into gastrointestinal disease diagnosis represents a transformative step toward precision medicine, enhancing real-time accuracy in detecting multi-category lesions at earlier stages, including small bowel lesions and precancerous polyps, ultimately improving patient outcomes. However, the use of AI in clinical settings raises ethical considerations that extend beyond technological potential. Issues of patient privacy, data security, and potential diagnostic biases require careful attention. AI models must prioritize diverse and representative datasets to mitigate inequities and ensure diagnostic accuracy across populations. Furthermore, balancing AI with clinical expertise is crucial, positioning AI as a supportive tool rather than a replacement for physician judgment. Addressing these ethical challenges will support the responsible deployment of AI, through equitable contribution to patient-centered care.

A computer-aided detection (CAD) system for early esophagus carcinoma identification during endoscopy with narrow-band imaging (NBI) was evaluated in a large-scale, prospective, tandem, randomized controlled trial to assess its effectiveness. The study was registered at the Chinese Clinical Trial Registry (ChiCTR2100050654, 2021/09/01). Involving 3400 patients were randomly assigned to either routine (routine-first) or CAD-assisted (CAD-first) NBI endoscopy, followed by the other procedure, with targeted biopsies taken at the end of the second examination. The primary outcome was the diagnosis of 1 or more neoplastic lesion of esophagus during the first examination. The CAD-first group demonstrated a significantly higher neoplastic lesion detection rate (3.12%) compared to the routine-first group (1.59%) with a relative detection ratio of 1.96 (P = 0.0047). Subgroup analysis revealed a higher detection rate in junior endoscopists using CAD-first, while no significant difference was observed for senior endoscopists. The CAD system significantly improved esophageal neoplasm detection, particularly benefiting junior endoscopists.

Artificial intelligence (AI) holds the potential to transform the management of upper gastrointestinal (GI) conditions, such as Barrett's esophagus, esophageal squamous cell cancer, and early gastric cancer. Advancements in deep learning and convolutional neural networks offer improved diagnostic accuracy and reduced diagnostic variability across different clinical settings, particularly where human error or fatigue may impair diagnostic precision. Deep learning models have shown the potential to improve early cancer detection and lesion characterization, predict invasion depth, and delineate lesion margins with remarkable accuracy, all contributing to effective treatment planning. Several challenges, however, limit the broad application of AI in GI endoscopy, particularly in the upper GI tract. Subtle lesion morphology and restricted diversity in training datasets, which are often sourced from specialized centers, may constrain the generalizability of AI models in various clinical settings. Furthermore, the "black box" nature of some AI systems can impede explainability and clinician trust. To address these issues, efforts are underway to incorporate multimodal data, such as combining endoscopic and histopathologic imaging, to bolster model robustness and transparency. In the future, AI promises substantial advancements in automated real-time endoscopic guidance, personalized risk assessment, and optimized biopsy decision making. As it evolves, it would substantially impact not only early diagnosis and prognosis, but also the cost-effectiveness of managing upper GI diseases, ultimately leading to improved patient outcomes and more efficient health care delivery.

Endoscopic diagnosis of early gastric cancer (EGC) is a challenge. It is not clear whether deep convolutional neural network (DCNN) model could improve the endoscopists' diagnostic performance.

We established a DCNN-assisted system and found that accuracy of diagnosis is higher than endoscopists. We prospectively collected an independent image test set of 1289 images and a video test set of 130 patients from three endoscopic centers to compare the diagnostic efficacy of 12 endoscopists before and after DCNN model assistance. Accuracy, sensitivity, specificity, time, and AUC were the main indicators for comparison.

The DCNN model discriminated EGC from the control group (including ulcers and chronic gastritis) with an AUC of 0.917, a sensitivity of 93.38% (95% CI 91.09-95.12%), and a specificity of 90.07% (95% CI 87.59-92.10%) in the image dataset. The video test dataset have an AUC of 0.930, a sensitivity of 96.92% (95% CI 88.83-99.78%), and a specificity of 89.23% (95% CI 79.11-94.98%). The diagnostic performance of novice endoscopists was comparable to those of expert endoscopists with the DCNN model's assistance (accuracy: 95.22 vs. 96.16%) in image test dataset. In the video test, the novice endoscopists, accuracy after DCNN assistance was also improved from 79.36 to 86.41%, and from 86.28 to 91.03% for expert endoscopists. The mean pairwise kappa value of endoscopists was increased significantly with the DCNN model's assistance (0.705-0.753 vs.0.767-0.890) in image testing, and (0.657-0.793 vs. 0.738-0.905) in video testing. The diagnostic duration reduced considerably with the assistance of the DCNN model from 7.09 ± 0.6 s to 5.05 ± 0.55 s in image test, and from 2392.17 ± 7.77 s to2378.34 ± 23.51 s in video test.

We developed a DCNN-assisted diagnostic system. And the system can improve the diagnostic performance of endoscopists and help novice endoscopists achieve diagnostic accuracy comparable to that of expert endoscopists.

The surge in artificial intelligence (AI) interventions in primary care trials lacks a study on reporting quality.

This study aimed to systematically evaluate the reporting quality of both published randomized controlled trials (RCTs) and protocols for RCTs that investigated AI interventions in primary care.

PubMed, Embase, Cochrane Library, MEDLINE, Web of Science, and CINAHL databases were searched for RCTs and protocols on AI interventions in primary care until November 2024. Eligible studies were published RCTs or full protocols for RCTs exploring AI interventions in primary care. The reporting quality was assessed using CONSORT-AI (Consolidated Standards of Reporting Trials-Artificial Intelligence) and SPIRIT-AI (Standard Protocol Items: Recommendations for Interventional Trials-Artificial Intelligence) checklists, focusing on AI intervention-related items.

A total of 11,711 records were identified. In total, 19 published RCTs and 21 RCT protocols for 35 trials were included. The overall proportion of adequately reported items was 65% (172/266; 95% CI 59%-70%) and 68% (214/315; 95% CI 62%-73%) for RCTs and protocols, respectively. The percentage of RCTs and protocols that reported a specific item ranged from 11% (2/19) to 100% (19/19) and from 10% (2/21) to 100% (21/21), respectively. The reporting of both RCTs and protocols exhibited similar characteristics and trends. They both lack transparency and completeness, which can be summarized in three aspects: without providing adequate information regarding the input data, without mentioning the methods for identifying and analyzing performance errors, and without stating whether and how the AI intervention and its code can be accessed.

The reporting quality could be improved in both RCTs and protocols. This study helps promote the transparent and complete reporting of trials with AI interventions in primary care.

The progression of malignant tumors leads to the development of secondary tumors in various organs, including bones, the brain, liver, and lungs. This metastatic process severely impacts the prognosis of patients, significantly affecting their quality of life and survival rates. Research efforts have consistently focused on the intricate mechanisms underlying this process and the corresponding clinical management strategies. Consequently, a comprehensive understanding of the biological foundations of tumor metastasis, identification of pivotal signaling pathways, and systematic evaluation of existing and emerging therapeutic strategies are paramount to enhancing the overall diagnostic and treatment capabilities for metastatic tumors. However, current research is primarily focused on metastasis within specific cancer types, leaving significant gaps in our understanding of the complex metastatic cascade, organ-specific tropism mechanisms, and the development of targeted treatments. In this study, we examine the sequential processes of tumor metastasis, elucidate the underlying mechanisms driving organ-tropic metastasis, and systematically analyze therapeutic strategies for metastatic tumors, including those tailored to specific organ involvement. Subsequently, we synthesize the most recent advances in emerging therapeutic technologies for tumor metastasis and analyze the challenges and opportunities encountered in clinical research pertaining to bone metastasis. Our objective is to offer insights that can inform future research and clinical practice in this crucial field.

Gastrointestinal endoscopy has been widely used in the diagnosis and treatment of gastrointestinal diseases. A great many of studies on gastrointestinal endoscopy have been done.

To analyze the characteristics of top 100 cited articles on gastrointestinal endoscopy.

A bibliometric analysis was conducted. The publications and their features were extracted from the Web of Science Core Collection, Science Citation Index-Expanded database. Excel, Web of Science database and SPSS software were used to perform the statistical description and analysis. VOSviewer software and MapChart were responsible for the visualizations.

The top 100 cited articles were published between 1976 and 2022. The guidelines (52%) and clinical trials (37%) are the main article types, and average publication year of the guidelines is much later than that of the clinical trials (2015 vs 1998). Among the clinical trials, diagnostic study (27.0%), cohort study (21.6%), case series (13.5%) and cross-sectional study (10.8%) account for a large proportion. Average citations of different study types and designs of the enrolled studies are of no significant differences. Most of the 100 articles were published by European authors and recorded by the endoscopic journals (65%). Top journals in medicine, such as the Lancet, New England Journal of Medicine and JAMA, also reported studies in this field. The hot spots of involved diseases include neoplasm or cancer-related diseases, inflammatory diseases, obstructive diseases, gastrointestinal hemorrhage and ulcer. Endoscopic surgery, endoscopic therapy and stent placement are frequently studied.

Our research contributes to delineating the field and identifying the characteristics of the most highly cited articles. It is noteworthy that there is a significantly smaller number of clinical trials included compared to guidelines, indicating potential areas for future high-quality clinical trials.

The implementation of computer-aided detection (CAD) devices in esophagogastroduodenoscopy (EGD) could autonomously identify gastric precancerous lesions and neoplasms and reduce the miss rate of gastric neoplasms in prospective trials. However, there is still insufficient evidence of their use in real-life clinical practice.

A real-world, two-center study was conducted at Wenzhou Central Hospital (WCH) and Renmin Hospital of Wuhan University (RHWU). High biopsy rate and low biopsy rate strategies were adopted, and CAD devices were applied in 2019 and 2021 at WCH and RHWU, respectively. We compared differences in gastric precancerous and neoplasm detection of EGD before and after the use of CAD devices in the first half of the year.

A total of 33 885 patients were included and 32 886 patients were ultimately analyzed. In WCH of which biopsy rate >95%, with the implementation of CAD, more the number of early gastric cancer divided by all gastric neoplasm (EGC/GN) (0.35% vs 0.59%, P = 0.028, OR [95% CI] = 1.65 [1.0-2.60]) was found, while gastric neoplasm detection rate (1.39% vs 1.36%, P = 0.897, OR [95% CI] = 0.98 [0.76-1.26]) remained stable. In RHWU of which biopsy rate <20%, the gastric neoplasm detection rate (1.78% vs 3.23%, P < 0.001, OR [95% CI] = 1.84 [1.33-2.54]) nearly doubled after the implementation of CAD, while there was no significant change in the EGC/GN.

The application of CAD devices devoted to distinct increases in gastric neoplasm detection according to different biopsy strategies, which implied that CAD devices demonstrated assistance on gastric neoplasm detection while varied effectiveness according to different implementation scenarios.

Pre-training deep learning models with large data sets of natural images, such as ImageNet, has become the standard for endoscopic image analysis. This approach is generally superior to training from scratch, due to the scarcity of high-quality medical imagery and labels. However, it is still unknown whether the learned features on natural imagery provide an optimal starting point for the downstream medical endoscopic imaging tasks. Intuitively, pre-training with imagery closer to the target domain could lead to better-suited feature representations. This study evaluates whether leveraging in-domain pre-training in gastrointestinal endoscopic image analysis has potential benefits compared to pre-training on natural images. To this end, we present a dataset comprising of 5,014,174 gastrointestinal endoscopic images from eight different medical centers (GastroNet-5M), and exploit self-supervised learning with SimCLRv2, MoCov2 and DINO to learn relevant features for in-domain downstream tasks. The learned features are compared to features learned on natural images derived with multiple methods, and variable amounts of data and/or labels (e.g. Billion-scale semi-weakly supervised learning and supervised learning on ImageNet-21k). The effects of the evaluation is performed on five downstream data sets, particularly designed for a variety of gastrointestinal tasks, for example, GIANA for angiodyplsia detection and Kvasir-SEG for polyp segmentation. The findings indicate that self-supervised domain-specific pre-training, specifically using the DINO framework, results into better performing models compared to any supervised pre-training on natural images. On the ResNet50 and Vision-Transformer-small architectures, utilizing self-supervised in-domain pre-training with DINO leads to an average performance boost of 1.63% and 4.62%, respectively, on the downstream datasets. This improvement is measured against the best performance achieved through pre-training on natural images within any of the evaluated frameworks. Moreover, the in-domain pre-trained models also exhibit increased robustness against distortion perturbations (noise, contrast, blur, etc.), where the in-domain pre-trained ResNet50 and Vision-Transformer-small with DINO achieved on average 1.28% and 3.55% higher on the performance metrics, compared to the best performance found for pre-trained models on natural images. Overall, this study highlights the importance of in-domain pre-training for improving the generic nature, scalability and performance of deep learning for medical image analysis. The GastroNet-5M pre-trained weights are made publicly available in our repository: huggingface.co/tgwboers/GastroNet-5M_Pretrained_Weights.

Gastric cancer represents a significant global health challenge with elevated incidence and mortality rates, highlighting the need for advancements in diagnostic and therapeutic strategies. This review paper addresses the critical need for a thorough synthesis of the role of artificial intelligence (AI) in the management of gastric cancer. It provides an in-depth analysis of current AI applications, focusing on their contributions to early diagnosis, treatment planning, and outcome prediction. The review identifies key gaps and limitations in the existing literature by examining recent studies and technological developments. It aims to clarify the evolution of AI-driven methods and their impact on enhancing diagnostic accuracy, personalizing treatment strategies, and improving patient outcomes. The paper emphasizes the transformative potential of AI in overcoming the challenges associated with gastric cancer management and proposes future research directions to further harness AI's capabilities. Through this synthesis, the review underscores the importance of integrating AI technologies into clinical practice to revolutionize gastric cancer management.

Recent advancements in artificial intelligence (AI) have significantly impacted the field of gastrointestinal (GI) endoscopy, with applications spanning a wide range of clinical indications. The central goals for AI in GI endoscopy are to improve endoscopic procedural performance and quality assessment, optimize patient outcomes, and reduce administrative burden. Despite early progress, such as Food and Drug Administration approval of the first computer-aided polyp detection system in 2021, there are numerous important challenges to be faced on the path toward broader adoption of AI algorithms in clinical endoscopic practice.

Numerous Deep Learning (DL) classification models have been developed for a large spectrum of medical image analysis applications, which promises to reshape various facets of medical practice. Despite early advances in DL model validation and implementation, which encourage healthcare institutions to adopt them, a fundamental questions remain: how can these models effectively handle domain shift? This question is crucial to limit DL models performance degradation. Medical data are dynamic and prone to domain shift, due to multiple factors. Two main shift types can occur over time: (1) covariate shift mainly arising due to updates to medical equipment and (2) concept shift caused by inter-grader variability. To mitigate the problem of domain shift, existing surveys mainly focus on domain adaptation techniques, with an emphasis on covariate shift. More generally, no work has reviewed the state-of-the-art solutions while focusing on the shift types. This paper aims to explore existing domain generalization methods for DL-based classification models through a systematic review of literature. It proposes a taxonomy based on the shift type they aim to solve. Papers were searched and gathered on Scopus till 10 April 2023, and after the eligibility screening and quality evaluation, 77 articles were identified. Exclusion criteria included: lack of methodological novelty (e.g., reviews, benchmarks), experiments conducted on a single mono-center dataset, or articles not written in English. The results of this paper show that learning based methods are emerging, for both shift types. Finally, we discuss future challenges, including the need for improved evaluation protocols and benchmarks, and envisioned future developments to achieve robust, generalized models for medical image classification.

While Artificial Intelligence (AI) has the potential to transform the field of diagnostic radiology, important obstacles still inhibit its integration into clinical environments. Foremost among them is the inability to integrate clinical information and prior and concurrent imaging examinations, which can lead to diagnostic errors that could irreversibly alter patient care. For AI to succeed in modern clinical practice, model training and algorithm development need to account for relevant background information that may influence the presentation of the patient in question. While AI is often remarkably accurate in distinguishing binary outcomes-hemorrhage vs. no hemorrhage; fracture vs. no fracture-the narrow scope of current training datasets prevents AI from examining the entire clinical context of the image in question. In this article, we provide an overview of the ways in which failure to account for clinical data and prior imaging can adversely affect AI interpretation of imaging studies. We then showcase how emerging techniques such as multimodal fusion and combined neural networks can take advantage of both clinical and imaging data, as well as how development strategies like domain adaptation can ensure greater generalizability of AI algorithms across diverse and dynamic clinical environments.

Gastric cancer ranks fifth for incidence and fourth in the leading causes of mortality worldwide. In this study, we aimed to validate previously developed artificial intelligence (AI) computer-aided detection (CADe) algorithm, called ALPHAON® in detecting gastric neoplasm.

We used the retrospective data of 500 still images, including 5 benign gastric ulcers, 95 with gastric cancer, and 400 normal images. Thereby we validated the CADe algorithm measuring accuracy, sensitivity, and specificity with the result of receiver operating characteristic curves (ROC) and area under curve (AUC) in addition to comparing the diagnostic performance status of four expert endoscopists, four trainees, and four beginners from two university-affiliated hospitals with CADe algorithm. After a washing-out period of over 2 weeks, endoscopists performed gastric detection on the same dataset of the 500 endoscopic images again marked by ALPHAON®.

The CADe algorithm presented high validity in detecting gastric neoplasm with accuracy (0.88, 95% CI: 0.85 to 0.91), sensitivity (0.93, 95% CI: 0.88 to 0.98), specificity (0.87, 95% CI: 0.84 to 0.90), and AUC (0.962). After a washing-out period of over 2 weeks, overall validity improved in the trainee and beginner groups with the assistance of ALPHAON®. Significant improvement was present, especially in the beginner group (accuracy 0.94 (0.93 to 0.96) p < 0.001, sensitivity 0.87 (0.82 to 0.92) p < 0.001, specificity 0.96 (0.95 to 0.97) p < 0.001).

The high validation performance state of the CADe algorithm system was verified. Also, ALPHAON® has demonstrated its potential to serve as an endoscopic educator for beginners improving and making progress in sensitivity and specificity.

To develop and validate an artificial intelligence diagnostic model for identifying calcified lumbar disc herniation based on lateral lumbar magnetic resonance imaging(MRI).

During the period from January 2019 to March 2024, patients meeting the inclusion criteria were collected. All patients had undergone both lumbar spine MRI and computed tomography(CT) examinations, with regions of interest (ROI) clearly marked on the lumbar sagittal MRI images. The participants were then divided into separate sets for training, testing, and external validation. Ultimately, we developed a deep learning model using the ResNet-34 algorithm model and evaluated its diagnostic efficacy.

A total of 1,224 eligible patients were included in this study, consisting of 610 males and 614 females, with an average age of 53.34 ± 10.61 years. Notably, the test datasets displayed an impressive classification accuracy rate of 91.67%, whereas the external validation datasets achieved a classification accuracy rate of 88.76%. Among the test datasets, the ResNet34 model outperformed other models, yielding the highest area under the curve (AUC) of 0.96 (95% CI: 0.93, 0.99). Additionally, the ResNet34 model also exhibited superior performance in the external validation datasets, exhibiting an AUC of 0.88 (95% CI: 0.80, 0.93).

In this study, we established a deep learning model with excellent performance in identifying calcified intervertebral discs, thereby offering a valuable and efficient diagnostic tool for clinical surgeons.

This study aims to evaluate the value of super resolution (SR) technology in augmenting the quality of digestive endoscopic images.

In the retrospective study, we employed two advanced SR models, i.e., SwimIR and ESRGAN. Two discrete datasets were utilized, with training conducted using the dataset of the First Affiliated Hospital of Soochow University (12,212 high-resolution images) and evaluation conducted using the HyperKvasir dataset (2,566 low-resolution images). Furthermore, an assessment of the impact of enhanced low-resolution images was conducted using a 5-point Likert scale from the perspectives of endoscopists. Finally, two endoscopic image classification tasks were employed to evaluate the effect of SR technology on computer vision (CV).

SwinIR demonstrated superior performance, which achieved a PSNR of 32.60, an SSIM of 0.90, and a VIF of 0.47 in test set. 90 % of endoscopists supported that SR preprocessing moderately ameliorated the readability of endoscopic images. For CV, enhanced images bolstered the performance of convolutional neural networks, whether in the classification task of Barrett's esophagus (improved F1-score: 0.04) or Mayo Endoscopy Score (improved F1-score: 0.04).

SR technology demonstrates the capacity to produce high-resolution endoscopic images. The approach enhanced clinical readability and CV models' performance of low-resolution endoscopic images.

The objective of this study is to investigate the efficacy of behavioral activation (BA), a novel psychological intervention, in ameliorating psychological distress and anxiety symptoms among patients diagnosed with esophageal and gastric cancer, as well as the mediating role of self-efficacy between BA and psychological distress.

A total of 139 patients diagnosed with esophageal and gastric cancer were recruited in China from March 2023 to October 2023 and randomly assigned to either the BA plus care as usual group (BA+CAU group) or the care as usual group (CAU group). Pre- and post-intervention questionnaires, including the Psychological Distress Thermometer (DT), Generalized anxiety disorder 7-item (GAD-7) Scale, General Self-Efficacy Scale (GSES) and the activation subscale of Behavioral Activation for Depression Scale (BADS-A), were administered.

Generalized estimating equation analyses revealed that, compared to usual care alone, combining BA with usual care significantly ameliorated psychological distress, anxiety as well as improved self-efficacy and activation. The mediation analysis revealed that self-efficacy served as a mediator in the relationship between activation and psychological distress.

BA primarily based on telephone or WeChat can not only directly ameliorates psychological distress and anxiety symptoms in patients with esophageal cancer and gastric cancer but also indirectly alleviates psychological distress by enhancing self-efficacy. The study also demonstrates the potential of BA in cancer patients, a skill that can be effectively acquired by primary care workers without specialized training and implemented more flexible.

NCT06348940.

Deep Learning (DL) drives academics to create models for cancer diagnosis using medical image processing because of its innate ability to recognize difficult-to-detect patterns in complex, noisy, and massive data. The use of deep learning algorithms for real-time cancer diagnosis is explored in depth in this work. Real-time medical diagnosis determines the illness or condition that accounts for a patient's symptoms and outward physical manifestations within a predetermined time frame. With a waiting period of anywhere between 5 days and 30 days, there are currently several ways, including screening tests, biopsies, and other prospective methods, that can assist in discovering a problem, particularly cancer. This article conducts a thorough literature review to understand how DL affects the length of this waiting period. In addition, the accuracy and turnaround time of different imaging modalities is evaluated with DL-based cancer diagnosis. Convolutional neural networks are critical for real-time cancer diagnosis, with models achieving up to 99.3% accuracy. The effectiveness and cost of the infrastructure required for real-time image-based medical diagnostics are evaluated. According to the report, generalization problems, data variability, and explainable DL are some of the most significant barriers to using DL in clinical trials. Making DL applicable for cancer diagnosis will be made possible by explainable DL.

The literature pertaining to surveillance following treatment for esophageal squamous cell carcinoma (SCC) was reviewed and summarized, encompassing the current status and future perspectives. Analysis of the standardized mortality and incidence ratios for these cancers indicates an elevated risk of cancer in the oral cavity, pharynx, larynx, and lungs among patients with esophageal SCC compared to the general population. To enhance the efficacy of surveillance for these metachronous cancers, risk stratification is needed. Various factors, including multiple Lugol-voiding lesions, multiple foci of dilated vascular areas, young age, and high mean corpuscular volume, have been identified as predictors of metachronous SCCs. Current practice involves stratifying the risk of metachronous esophageal and head/neck SCCs based on the presence of multiple Lugol-voiding lesions. Endoscopic surveillance, scheduled 6-12 months post-endoscopic resection, has demonstrated effectiveness, with over 90% of metachronous esophageal SCCs treatable through minimally invasive modalities. Narrow-band imaging emerges as the preferred surveillance method for esophageal and head/neck SCC based on comparative studies of various imaging techniques. Innovative approaches, such as artificial intelligence-assisted detection systems and radiofrequency ablation of high-risk background mucosa, may improve outcomes in patients following endoscopic resection.

Oesophagogastroduodenoscopy (OGD) quality and identification of the early upper gastrointestinal (UGI) neoplasm play an important role in detecting the UGI neoplasm. However, the optimal method for quality control in daily OGD procedures is currently lacking. We aimed to evaluate the efficacy of a real-time intelligent quality-control system (IQCS), which combines OGD quality control with lesion detection of early UGI neoplasms.

We performed a multicentre, single-blinded, randomised controlled trial at 6 hospitals in China. Patients aged 40-80 years old who underwent painless OGD were screened for enrolment in this study. Patients with a history of advanced UGI cancer, stenosis, or obstruction in UGI tract were excluded. Eligible subjects were randomly assigned (1:1) to either the routine or IQCS group to undergo standard OGD examination and OGD examination aided by IQCS, respectively. Patients were masked to the randomisation status. The primary outcome was the detection of early UGI neoplasms. All analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, NCT04720924.

Between January 16, 2021 and December 23, 2022, 1840 patients were randomised (IQCS group: 919, routine group: 921). The full analysis set consisted of 914 in the IQCS group and 915 in the routine group. The early UGI neoplasms detection rate in the IQCS group (6.1%, 56/914) was significantly higher than in the routine group (2.3%, 21/915; P = 0.0001). The IQCS group had fewer blind spots (2.3 vs. 6.2, P < 0.0001). The IQCS group had higher stomach cleanliness on cardia or fundus (99.5% vs. 87.9%, P < 0.0001), body (98.9% vs. 88.0%, P < 0.0001), angulus (99.8% vs. 88.4%, P < 0.0001) and antrum or pylorus (100.0% vs. 87.4%, P < 0.0001). The inspection time (576.2 vs. 574.5s, P = 0.91) and biopsy rate (57.2% vs. 56.6%, P = 0.83) were not different between the groups. The early UGI neoplasms detection rate in the IQCS group increased in both non-academic centres (RR = 3.319, 95% CI 1.277-9.176; P = 0.0094) and academic centres (RR = 2.416, 95% CI 1.301-4.568; P = 0.0034). The same improvements were observed for both less-experienced endoscopists (RR = 2.650, 95% CI 1.330-5.410; P = 0.0034) and experienced endoscopists (RR = 2.710, 95% CI 1.226-6.205; P = 0.010). No adverse events or serious adverse events were reported in the two groups.

The IQCS improved the OGD quality and increased early UGI neoplasm detection in different hospital types and endoscopist experiences. IQCS could play an important role in primary basic hospitals and non-expert endoscopists to improve the diagnostic accuracy of early UGI neoplasms. The effectiveness of IQCS in real-world clinical settings needs a larger population validation.

Key R&D Program of Shandong Province, China (Major Scientific and Technological Innovation Project), National Natural Science Foundation of China, the Taishan Scholars Program of Shandong Province, the National Key Research and Development Program of China, and the Shandong Provincial Natural Science Foundation.

Artificial intelligence (AI) using deep learning systems has recently been utilized in various medical fields. In the field of gastroenterology, AI is primarily implemented in image recognition and utilized in the realm of gastrointestinal (GI) endoscopy. In GI endoscopy, computer-aided detection/diagnosis (CAD) systems assist endoscopists in GI neoplasm detection or differentiation of cancerous or noncancerous lesions. Several AI systems for colorectal polyps have already been applied in colonoscopy clinical practices. In esophagogastroduodenoscopy, a few CAD systems for upper GI neoplasms have been launched in Asian countries. The usefulness of these CAD systems in GI endoscopy has been gradually elucidated.

In this review, we outline recent articles on several studies of endoscopic AI systems for GI neoplasms, focusing on esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastric cancer (GC), and colorectal polyps. In ESCC and EAC, computer-aided detection (CADe) systems were mainly developed, and a recent meta-analysis study showed sensitivities of 91.2% and 93.1% and specificities of 80% and 86.9%, respectively. In GC, a recent meta-analysis study on CADe systems demonstrated that their sensitivity and specificity were as high as 90%. A randomized controlled trial (RCT) also showed that the use of the CADe system reduced the miss rate. Regarding computer-aided diagnosis (CADx) systems for GC, although RCTs have not yet been conducted, most studies have demonstrated expert-level performance. In colorectal polyps, multiple RCTs have shown the usefulness of the CADe system for improving the polyp detection rate, and several CADx systems have been shown to have high accuracy in colorectal polyp differentiation.

Most analyses of endoscopic AI systems suggested that their performance was better than that of nonexpert endoscopists and equivalent to that of expert endoscopists. Thus, endoscopic AI systems may be useful for reducing the risk of overlooking lesions and improving the diagnostic ability of endoscopists.

We developed an artificial intelligence (AI)-based endoscopic ultrasonography (EUS) system for diagnosing the invasion depth of early gastric cancer (EGC), and we evaluated the performance of this system.

A total of 8280 EUS images from 559 EGC cases were collected from 11 institutions. Within this dataset, 3451 images (285 cases) from one institution were used as a development dataset. The AI model consisted of segmentation and classification steps, followed by the CycleGAN method to bridge differences in EUS images captured by different equipment. AI model performance was evaluated using an internal validation dataset collected from the same institution as the development dataset (1726 images, 135 cases). External validation was conducted using images collected from the other 10 institutions (3103 images, 139 cases).

The area under the curve (AUC) of the AI model in the internal validation dataset was 0.870 (95% CI: 0.796-0.944). Regarding diagnostic performance, the accuracy/sensitivity/specificity values of the AI model, experts (n = 6), and nonexperts (n = 8) were 82.2/63.4/90.4%, 81.9/66.3/88.7%, and 68.3/60.9/71.5%, respectively. The AUC of the AI model in the external validation dataset was 0.815 (95% CI: 0.743-0.886). The accuracy/sensitivity/specificity values of the AI model (74.1/73.1/75.0%) and the real-time diagnoses of experts (75.5/79.1/72.2%) in the external validation dataset were comparable.

Our AI model demonstrated a diagnostic performance equivalent to that of experts.

Recognition of gastric conditions during endoscopy exams, including gastric cancer, usually requires specialized training and a long learning curve. Besides that, the interobserver variability is frequently high due to the different morphological characteristics of the lesions and grades of mucosal inflammation. In this sense, artificial intelligence tools based on deep learning models have been developed to support physicians to detect, classify, and predict gastric lesions more efficiently. Even though a growing number of studies exists in the literature, there are multiple challenges to bring a model to practice in this field, such as the need for more robust validation studies and regulatory hurdles. Therefore, the aim of this review is to provide a comprehensive assessment of the current use of artificial intelligence applied to endoscopic imaging to evaluate gastric precancerous and cancerous lesions and the barriers to widespread implementation of this technology in clinical routine.

Early whitish gastric neoplasms can be easily misdiagnosed; differential diagnosis of gastric whitish lesions remains a challenge. We aim to build a deep learning (DL) model to diagnose whitish gastric neoplasms and explore the effect of adding domain knowledge in model construction.

We collected 4558 images from two institutions to train and test models. We first developed two sole DL models (1 and 2) using supervised and semi-supervised algorithms. Then we selected diagnosis-related features through literature research and developed feature-extraction models to determine features including boundary, surface, roundness, depression, and location. Then predictions of the five feature-extraction models and sole DL model were combined and inputted into seven machine-learning (ML) based fitting-diagnosis models. The optimal model was selected as ENDOANGEL-WD (whitish-diagnosis) and compared with endoscopists.

Sole DL 2 had higher sensitivity (83.12% vs 68.67%, Bonferroni adjusted P = 0.024) than sole DL 1. Adding domain knowledge, the decision tree performed best among the seven ML models, achieving higher specificity than DL 1 (84.38% vs 72.27%, Bonferroni adjusted P < 0.05) and higher accuracy than DL 2 (80.47%, Bonferroni adjusted P < 0.001) and was selected as ENDOANGEL-WD. ENDOANGEL-WD showed better accuracy compared with 10 endoscopists (75.70%, P < 0.001).

We developed a novel system ENDOANGEL-WD combining domain knowledge and traditional DL to detect gastric whitish neoplasms. Adding domain knowledge improved the performance of traditional DL, which provided a novel solution for establishing diagnostic models for other rare diseases potentially.

The clinical decision-making regarding choosing surgery alone (SA) or surgery followed by postoperative adjuvant chemotherapy (SPOCT) in esophageal squamous cell carcinoma (ESCC) remains controversial. We aim to propose a pre-therapy PET/CT image-based deep learning approach to improve the survival benefit and clinical management of ESCC patients.

This retrospective multicenter study included 837 ESCC patients from three institutions. Prognostic biomarkers integrating six networks were developed to build an ESCC prognosis (ESCCPro) model and predict the survival probability of ESCC patients treated with SA and SPOCT. Patients who did not undergo surgical resection were in a control group. Overall survival (OS) was the primary end-point event. The expected improvement in survival prognosis with the application of ESCCPro to assign treatment protocols was estimated by comparing the survival of patients in each subgroup. Seven clinicians with varying experience evaluated how ESCCPro performed in assisting clinical decision-making.

In this retrospective multicenter study, patients receiving SA had a median OS 9.2 months longer than controls. No significant differences in survival were found between SA patients with predicted poor outcomes and the controls (p > 0.05). It was estimated that if ESCCPro was used to determine SA and SPOCT eligibility, the median OS in the ESCCPro-recommended SA group and SPOCT group would have been 15.3 months and 24.9 months longer, respectively. In addition, ESCCPro also significantly improved prognosis accuracy, certainty, and the efficiency of clinical experts.

ESCCPro assistance improved the survival benefit of ESCC patients and the clinical decision-making among the two treatment approaches.

The ESCCPro model for treatment decision-making is promising to improve overall survival in ESCC patients undergoing surgical resection and patients undergoing surgery followed by postoperative adjuvant chemotherapy.

ESCC is associated with a poor prognosis and unclear ideal treatments. ESCCPro predicts the survival of patients with ESCC and the expected benefit from SA. ESCCPro improves clinicians' stratification of patients' prognoses.

Accurate diagnosis and prognosis prediction are conducive to early intervention and improvement of medical care for natural killer/T cell lymphoma (NKTCL). Artificial intelligence (AI)-based systems are developed based on nasopharynx magnetic resonance imaging. The diagnostic systems achieve areas under the curve of 0.905-0.960 in detecting malignant nasopharyngeal lesions and distinguishing NKTCL from nasopharyngeal carcinoma in independent validation datasets. In comparison to human radiologists, the diagnostic systems show higher accuracies than resident radiologists and comparable ones to senior radiologists. The prognostic system shows promising performance in predicting survival outcomes of NKTCL and outperforms several clinical models. For patients with early-stage NKTCL, only the high-risk group benefits from early radiotherapy (hazard ratio = 0.414 vs. late radiotherapy; 95% confidence interval, 0.190-0.900, p = 0.022), while progression-free survival does not differ in the low-risk group. In conclusion, AI-based systems show potential in assisting accurate diagnosis and prognosis prediction and may contribute to therapeutic optimization for NKTCL.

Whole slide imaging (WSI) of Hematoxylin and Eosin-stained biopsy specimens has been used to predict chemoradiotherapy (CRT) response and overall survival (OS) of esophageal squamous cell carcinoma (ESCC) patients. This retrospective study collected 279 specimens in 89 non-surgical ESCC patients through endoscopic biopsy between January 2010 and January 2019. These patients were divided into a CRT response group (CR + PR group) and a CRT non-response group (SD + PD group). The WSIs have segmented approximately 1,206,000 non-overlapping patches. Two experienced pathologists manually delineated the eight types of tissues on 32 WSIs, including esophagus tumor cell (TUM), cancer-associated stroma (CAS), normal epithelium layer (NEL), smooth muscle (MUS), lymphocytes (LYM), Red cells (RED), debris (DEB), uneven areas (UNE). The chemoradiotherapy response prediction models were built using maximum relevance-minimum redundancy (MRMR) feature selection and least absolute shrinkage and selection operator (LASSO) regression. However, pathological features with p < 0.1 were selected and integrated to be further screened using a LASSO Cox regression model to build a multivariate Cox proportional hazards model for predicting the OS. The testing accuracy of the tissue classification model was 91.3 %. The pathological model created using two CAS in-depth features and eight TUM in-depth features performed best for the prediction of treatment response and achieved an AUC of 0.744. For the prediction of OS, the testing AUC of this model at one year and three years were 0.675 and 0.870, respectively. The TUM model showed the highest AUC at one year (0.712). With its high accuracy rate, the deep learning model has the potential to transform from bench to bedside in clinical practice, improve patient's quality of life, and prolong the OS rate.

Gastric cancer (GC) is one of the most common malignant tumors in the world, posing a serious threat to human health. Currently, gastric cancer treatment strategies emphasize a multidisciplinary team (MDT) consultation approach. However, there are numerous treatment guidelines and insights from clinical trials. The application of AI-based Clinical Decision Support System (CDSS) in tumor diagnosis and screening is increasing rapidly.

The purpose of this study is to (1) summarize the treatment decision process for GC according to the treatment guidelines in China, and then create a knowledge graph (KG) for GC, (2) based on aforementioned KG, built a CDSS and conducted an initial feasibility evaluation for the current system.

Firstly, we summarized the decision-making process for treatment of GC. Then, we extracted relevant decision nodes and relationships and utilized Neo4j to create the KG. After obtaining the initial node features for building the graph embedding model, graph embedding algorithm, such as Node2Vec and GraphSAGE, were used to construct the GC-CDSS. At last, a retrospective cohort study was used to compare the consistency between GC-CDSS and MDT in treatment decision making.

In current study, we introduce a GC-CDSS, which is constructed based on Chinese GC treatment guidelines knowledge graph (KG). In the KG, we define four types of nodes and four types of relationships, and it comprise a total of 207 nodes and 300 relationships. Regarding GC-CDSS, the system is capable of providing dynamic and personalized diagnostic and treatment recommendations based on the patient's condition. Furthermore, a retrospective cohort study is conducted to compare GC-CDSS recommendations with those of the MDT group, the overall consistency rate of treatment recommendations between the auxiliary decision system and MDT team is 92.96%.

We construct a GC treatment support system, GC-CDSS, based on KG. The GC-CDSS may help oncologists make treatment decisions more efficient and promote standardization in primary healthcare settings.